Here, we demonstrate that the three NPs, ANP, BNP, and CNP, possibly by functioning as Wnt/β-catenin signaling modulators, could be promising molecules for developing a PD-modifying therapy. The gene discussed is NPPA; the disease is Parkinson disease.